Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Steve Elms
AddedFeb 13, 2024
UpdatedMay 31, 2026
Steve Elms

Steve Elms

Board Member, Marker Therapeutics

Crunchbase

Steve Elms's Career

Marker Therapeutics
Marker Therapeutics

Houston, TX, US

Board Member· Board
ADMA Biologics
ADMA Biologics

Ramsey, NJ, US

Board Member· Board
Earlens
Earlens

Menlo Park, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Steve Elms's Career

Marker Therapeutics
Marker Therapeutics
Public$98.6M672018Houston, TX, US
Board Member· Board

Leadership at Marker Therapeutics

Mark BrukMark BrukCo-Founder
Juan VeraJuan VeraCo-Founder & CEO
John WilsonJohn WilsonBoard Member
Dave EansorDave EansorBoard Member

Similar to Marker Therapeutics

TScan TherapeuticsTScan TherapeuticsWaltham, MA, UST-Cell Therapiesest. 2018TScan TherapeuticsWaltham, MA, US · est. 2018

US-based company in Waltham, innovating T cell systems for advanced immunotherapy solutions.

Public · $197.5M137
ManaT BioManaT BioBaltimore, MD, USImmunotherapyest. 2020ManaT BioBaltimore, MD, US · est. 2020

Based in Baltimore, ManaT Bio is a biotech firm specializing in genetic and immunological therapies.

Series D · $72.1M50
Atara BiotherapeuticsAtara BiotherapeuticsSouth San Francisco, CA, UST-Cell Therapiesest. 2012Atara BiotherapeuticsSouth San Francisco, CA, US · est. 2012

Atara Biotherapeutics: A clinical-stage biotech firm dedicated to developing therapies for severe diseases.

Public · $499.8M334
Luminary TherapeuticsLuminary TherapeuticsMinneapolis, MN, USCell Therapyest. 2019Luminary TherapeuticsMinneapolis, MN, US · est. 2019

Luminary Therapeutic: Pioneering non-viral cell therapies for cancer and autoimmune diseases since 2019.

Pre-Seed · $2.7M30
ADMA Biologics
ADMA Biologics
Public$742.4M6172004Ramsey, NJ, US
Board Member· Board

Leadership at ADMA Biologics

Martha J. DemskiMartha J. DemskiBoard Member
Adam GrossmanAdam GrossmanBoard Member
Jerrold GrossmanJerrold GrossmanBoard Member

Similar to ADMA Biologics

Biomat USABiomat USALos Angeles, CA, USPlasma Collectionest. 1986Biomat USALos Angeles, CA, US · est. 1986

Grifols, established in 1950, operates over 175 plasma donation centers across the US, collecting protein-rich plasma for life-saving therapies.

Public · $1B328
AIM ImmunotechAIM ImmunotechOcala, FL, USTherapeuticsest. 1990AIM ImmunotechOcala, FL, US · est. 1990

US-based AIM ImmunoTech Inc. pioneers in developing therapeutics for cancer and immune disorders.

Public22
AdimabAdimabLebanon, NH, USTherapeutic Antibodiesest. 2007AdimabLebanon, NH, US · est. 2007

Adimab, LLC: A global biotech firm specializing in yeast-based therapeutic human antibodies.

Public · $45.5M149
MacroGenicsMacroGenicsRockville, MD, USest. 2000MacroGenicsRockville, MD, US · est. 2000

US-based MacroGenics, Inc. develops novel biologics for cancer, autoimmune disorders, and infectious diseases.

Public · $165.9M357
Earlens
Earlens
Series C$318.8M1372005Menlo Park, CA, US
Board Member· Board

Leadership at Earlens

Aftab KheraniAftab KheraniBoard Member
Rodney PerkinsRodney PerkinsFounder
Hank PlainHank PlainBoard Member
Bill FacteauBill FacteauBoard Member
David C HardieDavid C HardieBoard Member
Tom PrescottTom PrescottBoard Member

Similar to Earlens

HearGlassHearGlassNew York City, NY, USHearing Aidsest. 2009HearGlassNew York City, NY, US · est. 2009

High-tech provider developing advanced hearing aids for individuals with hearing loss.

Angel · $200k7
PionEar TechnologiesPionEar TechnologiesAllston-Brighton, MA, USMedical DevicesPionEar TechnologiesAllston-Brighton, MA, US

PionEar Technologies: Innovating medical devices for ear and hearing disorders.

Angel · $50k10
Soundwave HearingSoundwave HearingOak Brook, IL, USHearing Aids, Softwareest. 2017Soundwave HearingOak Brook, IL, US · est. 2017

Soundwave Hearing: A health tech firm developing smart hearing aids using machine learning.

Series A · $2.3M9
AudioFocusAudioFocusOakland, CA, USHearing AidsAudioFocusOakland, CA, US

Hearing aids with ML for clear hearing in noise, by experts in AI and auditory science.

Seed · $150k6

Steve Elms's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Steve Elms

Jerry ColemanJerry ColemanFounder · Invitation HomesLori HuLori HuBoard Member · BlackThorn TherapeuticsShaun AndrikopoulosShaun AndrikopoulosFounder · Teton Sports & Spine ImagingRobert J. CarusoRobert J. CarusoBoard Member · Human ElevationJonathan FlemingJonathan FlemingBoard of Directors · Quiver BioscienceGreg FasulloGreg FasulloBoard Member · EnTouch Controls